Cancer risk in diabetic patients treated with metformin: A systematic review and meta-analysis

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Noto, Hiroshi ^a   Goto, Atsushi ^a   Tsujimoto, Tetsuro ^a   Noda, Mitsuhiko ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; ANTIDIABETIC AGENT;

ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CAUSE OF DEATH; COLORECTAL CANCER; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DRUG EFFICACY; DRUG USE; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; RISK ASSESSMENT; RISK REDUCTION; SYSTEMATIC REVIEW; CLINICAL TRIAL (TOPIC); INCIDENCE; META ANALYSIS (TOPIC); NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK FACTOR;

CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; META-ANALYSIS AS TOPIC; METFORMIN; NEOPLASMS; RISK FACTORS;

EID: 84858695046     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033411     Document Type: Article

References (98)

1. Larsson SC, Mantzoros CS, Wolk A, (2007) Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 121: 856-862.
2. Friberg E, Orsini N, Mantzoros CS, Wolk A, (2007) Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia 50: 1365-1374.
3. Larsson SC, Orsini N, Brismar K, Wolk A, (2006) Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 49: 2819-2823.
4. El-Serag HB, Hampel H, Javadi F, (2006) The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 4: 369-380.
5. Larsson SC, Orsini N, Wolk A, (2005) Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 97: 1679-1687.
6. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M, (2005) Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 92: 2076-2083.
7. Everhart J, Wright D, (1995) Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 273: 1605-1609.
8. Bonovas S, Filioussi K, Tsantes A, (2004) Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia 47: 1071-1078.
9. Kasper JS, Giovannucci E, (2006) A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15: 2056-2062.
10. Mitri J, Castillo J, Pittas AG, (2008) Diabetes and risk of Non-Hodgkin's lymphoma: a meta-analysis of observational studies. Diabetes Care 31: 2391-2397.
11. Chao C, Page JH, (2008) Type 2 diabetes mellitus and risk of non-Hodgkin lymphoma: a systematic review and meta-analysis. Am J Epidemiol 168: 471-480.
12. Noto H, Osame K, Sasazuki T, Noda M, (2010) Substantially increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis of epidemiologic evidence in Japan. J Diabetes Complications 24: 345-353.
13. Noto H, Tsujimoto T, Sasazuki T, Noda M, (2011) Significantly Increased Risk of Cancer in Patients with Diabetes Mellitus. Endocrine Practice 17: 616-628.
14. Noto H, Tsujimoto T, Noda M, (in press) Significantly Increased Risk of Cancer in Diabetes Mellitus Patients: A meta-analysis of epidemiologic evidence in Asians and non-Asians. Journal of Diabetes Investigation.
15. van Staa TP, Patel D, Gallagher AM, de Bruin ML, (2011) Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data. Diabetologia Nov 30. [Epub ahead of print].
16. Wotton CJ, Yeates DG, Goldacre MJ, (2011) Cancer in patients admitted to hospital with diabetes mellitus aged 30 years and over: record linkage studies. Diabetologia 54: 527-534.
17. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, et al. (2009) Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32: 193-203.
18. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, et al. (2010) Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 3: 1451-1461.
19. Zhang ZJ, Zheng ZJ, Kan H, Song Y, Cui W, et al. (2011) Reduced Risk of Colorectal Cancer With Metformin Therapy in Patients With Type 2 Diabetes: A meta-analysis. Diabetes Care 34: 2323-2328.
20. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, et al. (2008) Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 300: 2754-2764.
21. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, et al. (2010) Postoperative mortality in cancer patients with preexisting diabetes: systematic review and meta-analysis. Diabetes Care 33: 931-939.
22. Schulz KF, Altman DG, Moher D, (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 152: 726-732.
23. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, et al. (2008) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 61: 344-349.
24. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, et al. (1999) Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 354: 1896-1900.
25. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al. (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283: 2008-2012.
26. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 151: W65-94.
27. Bowker SL, Yasui Y, Veugelers P, Johnson JA, (2010) Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Diabetologia 53: 1631-1637.
28. Donadon V, Balbi M, Ghersetti M, Grazioli S, Perciaccante A, et al. (2009) Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World journal of gastroenterology: WJG 15: 2506-2511.
29. Donadon V, Balbi M, Mas MD, Casarin P, Zanette G, (2010) Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver International 30: 750-758.
30. Yang X, So WY, Ma RC, Kong AP, Lee HM, et al. (2011) Low HDL cholesterol, metformin use, and cancer risk in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes Care 34: 375-380.
31. He XX, Tu SM, Lee MH, Yeung SC, (2011) Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann Oncol 22: 2640-2645.
32. Chen TM, Lin CC, Huang PT, Wen CF, (2011) Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation. Journal of gastroenterology and hepatology 26: 858-865.
33. Nkontchou G, Cosson E, Aout M, Mahmoudi A, Bourcier V, et al. (2011) Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. The Journal of clinical endocrinology and metabolism 96: 2601-2608.
34. Patel T, Hruby G, Badani K, Abate-Shen C, McKiernan JM, (2010) Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin. Urology 76: 1240-1244.
35. Bowker SL, Majumdar SR, Veugelers P, Johnson JA, (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29: 254-258.
36. Currie CJ, Poole CD, Gale EA, (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52: 1766-1777.
37. Hense HW, Kajuter H, Wellmann J, Batzler WU, (2011) Cancer incidence in type 2 diabetes patients- first results from a feasibility study of the D2C cohort. Diabetology & metabolic syndrome 3: 15.
38. Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, et al. (2010) Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 33: 322-326.
39. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, et al. (2011) Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC cancer 11: 20.
40. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, et al. (2009) New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32: 1620-1625.
41. Mellbin LG, Malmberg K, Norhammar A, Wedel H, Ryden L, (2011) Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study. Diabetologia 54: 1308-1317.
42. Morden NE, Liu SK, Smith J, Mackenzie TA, Skinner J, et al. (2011) Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. Diabetes Care 34: 1965-1971.
43. Tseng CH, (2011) Diabetes and risk of prostate cancer: a study using the National Health Insurance. Diabetes Care 34: 616-621.
44. Tseng CH, (2011) Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. Diabetologia 54: 2009-2015.
45. Yang X, So WY, Ma RC, Yu LW, Ko GT, et al. (2010) Use of sulphonylurea and cancer in type 2 diabetes-The Hong Kong Diabetes Registry. Diabetes research and clinical practice 90: 343-351.
46. Home PD, Kahn SE, Jones NP, Noronha D, Beck-Nielsen H, et al. (2010) Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia 53: 1838-1845.
47. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, et al. (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355: 2427-2443.
48. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, et al. (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373: 2125-2135.
49. (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352: 854-865.
50. Azoulay L, Dell'Aniello S, Gagnon B, Pollak M, Suissa S, (2011) Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20: 337-344.
51. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR, (2010) Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 33: 1304-1308.
52. Bosco JL, Antonsen S, Sorensen HT, Pedersen L, Lash TL, (2011) Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20: 101-111.
53. Hassan MM, Curley SA, Li D, Kaseb A, Davila M, et al. (2010) Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 116: 1938-1946.
54. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL, (2009) Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 137: 482-488.
55. Monami M, Lamanna C, Balzi D, Marchionni N, Mannucci E, (2009) Sulphonylureas and cancer: a case-control study. Acta diabetologica 46: 279-284.
56. Monami M, Colombi C, Balzi D, Dicembrini I, Giannini S, et al. (2011) Metformin and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 34: 129-131.
57. Wright JL, Stanford JL, (2009) Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer causes & control: CCC 20: 1617-1622.
58. Yang YX, Hennessy S, Lewis JD, (2004) Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 127: 1044-1050.
59. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ, (2006) Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367: 1747-1757.
60. White MF, (1997) The insulin signalling system and the IRS proteins. Diabetologia 40 (Suppl 2): S2-17.
61. Kim YI, (1998) Diet, lifestyle, and colorectal cancer: is hyperinsulinemia the missing link? Nutr Rev 56: 275-279.
62. Kaaks R, (1996) Nutrition, hormones, and breast cancer: is insulin the missing link? Cancer Causes Control 7: 605-625.
63. Giovannucci E, (1995) Insulin and colon cancer. Cancer Causes Control 6: 164-179.
64. Yu H, Berkel H, (1999) Insulin-like growth factors and cancer. J La State Med Soc 151: 218-223.
65. Zhang W, Thornton WH, MacDonald RS, (1998) Insulin-like growth factor-I and II receptor expression in rat colon mucosa are affected by dietary lipid intake. J Nutr 128: 158-165.
66. Bruning PF, Bonfrer JM, van Noord PA, Hart AA, de Jong-Bakker M, et al. (1992) Insulin resistance and breast-cancer risk. Int J Cancer 52: 511-516.
67. Hu FB, Manson JE, Liu S, Hunter D, Colditz GA, et al. (1999) Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst 91: 542-547.
68. Silverman DT, Schiffman M, Everhart J, Goldstein A, Lillemoe KD, et al. (1999) Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer 80: 1830-1837.
69. Wolf I, Sadetzki S, Catane R, Karasik A, Kaufman B, (2005) Diabetes mellitus and breast cancer. Lancet Oncol 6: 103-111.
70. Le Roith D, (1997) Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N Engl J Med 336: 633-640.
71. Richardson LC, Pollack LA, (2005) Therapy insight: Influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol 2: 48-53.
72. Morss AS, Edelman ER, (2007) Glucose modulates basement membrane fibroblast growth factor-2 via alterations in endothelial cell permeability. J Biol Chem 282: 14635-14644.
73. Barclay AW, Petocz P, McMillan-Price J, Flood VM, Prvan T, et al. (2008) Glycemic index, glycemic load, and chronic disease risk-a meta-analysis of observational studies. Am J Clin Nutr 87: 627-637.
74. Gapstur SM, Gann PH, Lowe W, Liu K, Colangelo L, et al. (2000) Abnormal glucose metabolism and pancreatic cancer mortality. JAMA 283: 2552-2558.
75. Seow A, Yuan JM, Koh WP, Lee HP, Yu MC, (2006) Diabetes mellitus and risk of colorectal cancer in the Singapore Chinese Health Study. J Natl Cancer Inst 98: 135-138.
76. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, et al. (2005) Fasting serum glucose level and cancer risk in Korean men and women. JAMA 293: 194-202.
77. Stocks T, Rapp K, Bjorge T, Manjer J, Ulmer H, et al. (2009) Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts. PLoS Med 6: e1000201.
78. Abe R, Yamagishi S, (2008) AGE-RAGE system and carcinogenesis. Curr Pharm Des 14: 940-945.
79. Inoue M, Kurahashi N, Iwasaki M, Tanaka Y, Mizokami M, et al. (2009) Metabolic factors and subsequent risk of hepatocellular carcinoma by hepatitis virus infection status: a large-scale population-based cohort study of Japanese men and women (JPHC Study Cohort II). Cancer Causes Control 20: 741-750.
80. Johnson JA, Gale EA, (2010) Diabetes, insulin use, and cancer risk: are observational studies part of the solution-or part of the problem? Diabetes 59: 1129-1131.
81. Pocock SJ, Elbourne DR, (2000) Randomized trials or observational tribulations? N Engl J Med 342: 1907-1909.
82. McFarland MS, Cripps R, (2010) Diabetes mellitus and increased risk of cancer: focus on metformin and the insulin analogs. Pharmacotherapy 30: 1159-1178.
83. Grossmann M, Thomas MC, Panagiotopoulos S, Sharpe K, Macisaac RJ, et al. (2008) Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab 93: 1834-1840.
84. Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A, et al. (2004) Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 89: 5462-5468.
85. Ding EL, Song Y, Malik VS, Liu S, (2006) Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 295: 1288-1299.
86. Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AK, et al. (2010) Metformin: taking away the candy for cancer? European journal of cancer 46: 2369-2380.
87. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, et al. (2009) Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 27: 3297-3302.
88. Hosono K, Endo H, Takahashi H, Sugiyama M, Uchiyama T, et al. (2010) Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. Molecular carcinogenesis 49: 662-671.
89. Piccinni C, Motola D, Marchesini G, Poluzzi E, (2011) Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting. Diabetes Care.
90. Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, et al. (2011) Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes are 34: 916-922.
91. Giovannucci E, (2007) Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. The American journal of clinical nutrition 86: s836-842.
92. Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN, (2008) The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer prevention research 1: 369-375.
93. Algire C, Amrein L, Zakikhani M, Panasci L, Pollak M, (2010) Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocrine-related cancer 17: 351-360.
94. Raimondi S, Maisonneuve P, Lowenfels AB, (2009) Epidemiology of pancreatic cancer: an overview. Nature reviews Gastroenterology & hepatology 6: 699-708.
95. Schneider MB, Matsuzaki H, Haorah J, Ulrich A, Standop J, et al. (2001) Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 120: 1263-1270.
96. Xue F, Michels KB, (2007) Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. The American journal of clinical nutrition 86: s823-835.
97. Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD, et al. (2010) Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer prevention research 3: 1066-1076.
98. Yang YX, (2009) Do diabetes drugs modify the risk of pancreatic cancer? Gastroenterology 137: 412-415.